Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
MVP Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2022 · fourth_quarter · 4T
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Source: Senate LDA
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
MVP Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
MVP Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Food and Drug Amendments of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Food and Drug Amendments of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Food and Drug Amendments of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Food and Drug Amendments of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Food and Drug Amendments of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Food and Drug Amendments of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Food and Drug Amendments of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Food and Drug Amendments of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
FDASLA Act of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
FDASLA Act of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
FDASLA Act of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
FDASLA Act of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
FDASLA Act of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
FDASLA Act of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
FDASLA Act of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
FDASLA Act of 2022
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2022 · fourth_quarter · Q4
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2022 · third_quarter · Q3
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2022 · second_quarter · Q2
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act. Advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2022 · second_quarter · RR
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products, including: Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA appropriations.
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products, including: Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA appropriations.